Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:45:52.095Z.
Calculation as of: 2026-10-06T14:45:52.095Z.
Quote observation: 2026-10-06T14:17:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9f471510e2ba483dadfaa738129fdacbeb72ec081face8194c47abf0e776528
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$6.67M
EV/EBIT Ratio
N/A
TTM Avg
1748.82x
3Y Avg
1748.82x
5Y Avg
1748.82x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.76M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.78M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | N/A | 1748.82x | 1748.82x | 1748.82x |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | N/A | 1.45x | 7.74x | 7.74x |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.42M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.09M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.30M | N/A | 471.11x | 281.60x | 221.14x |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.33M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
